Review
109881 Aventis
Affiliations
- PMID: 12901234
Item in Clipboard
Review
109881 Aventis
Curr Opin Investig Drugs.
2003 Jun.
Abstract
109881 is an orally and intravenously active taxoid in development by Aventis Pharma (formerly Rhône-Poulenc Rorer) as a potential treatment for a variety of taxoid-resistant solid tumors, such as brain and lung cancers. As of April 2000, the compound was in phase IIa trials in the US, France, Belgium and Germany. Phase II trials were ongoing in May 2001, and the company was evaluating an oral formulation at this time.
Similar articles
-
BMS-247550 Bristol-Myers Squibb/GBF.Curr Opin Investig Drugs. 2003 Jun;4(6):746-56. Curr Opin Investig Drugs. 2003. PMID: 12901236 Review.
-
BAY-43-9006 Bayer/Onyx.Curr Opin Investig Drugs. 2003 Jun;4(6):757-63. Curr Opin Investig Drugs. 2003. PMID: 12901237 Review.
-
CMT-3. CollaGenex.Curr Opin Investig Drugs. 2003 Dec;4(12):1460-7. Curr Opin Investig Drugs. 2003. PMID: 14763133 Review.
-
MEN-10755. Menarini.Curr Opin Investig Drugs. 2003 Dec;4(12):1473-8. Curr Opin Investig Drugs. 2003. PMID: 14763135 Review.
-
Lapatinib ditosylate GlaxoSmithKline.IDrugs. 2003 Sep;6(9):886-93. IDrugs. 2003. PMID: 12964069 Review.
Cited by
-
Tubulin-interactive natural products as anticancer agents.J Nat Prod. 2009 Mar 27;72(3):507-15. doi: 10.1021/np800568j. J Nat Prod. 2009. PMID: 19125622 Free PMC article. Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Other Literature Sources
Research Materials
Miscellaneous